Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Deucravacitinib in Alopecia Areata
2020-000113-33Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Deucravacitinib arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in SALT score at Week 24. Started Oct 2022; status: completed.
02
Drugs
deucravacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2020-000113-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000113-33.